Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O<sup>6</sup>-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial

2016195 citationsJournal Article

Authors

Ulrich Herrlinger · Goethe University Frankfurt

Niklas Schäfer · Goethe University Frankfurt

Jörg Steinbach · Goethe University Frankfurt

Astrid Weyerbrock · Goethe University Frankfurt

Peter Hau · Goethe University Frankfurt

Roland Goldbrunner · Goethe University Frankfurt

Franziska Friedrich

Abstract

BEV+IRI resulted in a superior PFS-6 rate and median PFS compared with TMZ. However, BEV+IRI did not improve OS, potentially because of the high crossover rate. BEV+IRI did not alter QOL compared with TMZ.

Topics & Keywords

Glioma Diagnosis and Treatment Brain Metastases and Treatment Histone Deacetylase Inhibitors Research

Publication Details

Published in: Journal of Clinical Oncology

Volume 34, Issue 14, pp. 1611-1619

DOI: 10.1200/jco.2015.63.4691

Field-Weighted Citation Impact: 16.13

Command Palette

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O<sup>6</sup>-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial

Authors

Abstract

Topics & Keywords

Publication Details